Market Cap 2.64B
Revenue (ttm) 16.10M
Net Income (ttm) -198.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,235.84%
Debt to Equity Ratio 0.33
Volume 2,811,000
Avg Vol 2,344,350
Day's Range N/A - N/A
Shares Out 63.07M
Stochastic %K 7%
Beta 0.90
Analysts Strong Sell
Price Target $68.10

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
Benalish
Benalish Jul. 3 at 1:07 AM
1 · Reply
free2dream
free2dream Jul. 2 at 8:14 PM
$SRPT correction : SAREPTA SHOULD BE VALUED HIGHER THAN $MRNA ! Their progress in Huntington disease is ahead of $QURE . ELEVIDYS and other DMD therapies are extremely undervalued. Charge more money for it. It only cost investors $20B to develop, 2 kids died and investors got wiped out. TOTAL BULLSHIT !
2 · Reply
free2dream
free2dream Jul. 2 at 7:58 PM
$SRPT YOU AINT GOING TO FIND A BIOTECH COMPANY THIS UNDERVALUED ! $2B ARKET CAP on $2B market sale and right neck to neck with $QURE on huntington research. SAREPTA INVESTORS MOVE YOUR ASKS WAY UP , $200+
1 · Reply
Dkll303
Dkll303 Jul. 2 at 4:27 PM
$QURE $25 on the horizon once again …Matt will make sure of that !!! For his Leerink friends ..
0 · Reply
Dkll303
Dkll303 Jul. 2 at 4:26 PM
$QURE appears the SHIT didn’t stick !!!! But then Matt tries anything , even selling pieces to keep his ass from cold calling again
0 · Reply
Stef_Gee
Stef_Gee Jul. 2 at 2:09 PM
$QURE Struggling under VWAP ...
0 · Reply
MABA1
MABA1 Jul. 2 at 1:44 PM
$QURE I’m in
0 · Reply
LotOfAction
LotOfAction Jul. 2 at 12:05 PM
$QURE Sold half from 17s, letting the other half ride
0 · Reply
stu4
stu4 Jul. 1 at 10:48 AM
$QURE will Matt Kapu-shit throw shit against the wall again today …to see if it sticks ???? Probably All his friends like those of TRUMP , left for the holidays , ( ya know scum brokers that he was for years ) and the stock will drift ..no phone whispers to his click of broker friends
1 · Reply
stu4
stu4 Jul. 1 at 1:47 AM
$QURE ANOTHER BFD !!!
0 · Reply
Latest News on QURE
uniQure price target raised to $68 from $35 at Mizuho

2026-06-25T11:26:12.000Z - 9 days ago

uniQure price target raised to $68 from $35 at Mizuho


uniQure 4.95M share Spot Secondary priced at $45.50

2026-06-24T01:51:45.000Z - 10 days ago

uniQure 4.95M share Spot Secondary priced at $45.50


UniQure Stock (QURE) Gains on Public Offering Plans

2026-06-23T18:40:00.000Z - 11 days ago

UniQure Stock (QURE) Gains on Public Offering Plans


uniQure rises 7.6%

2026-06-23T15:04:50.000Z - 11 days ago

uniQure rises 7.6%


uniQure announces $150M offering of common stock

2026-06-22T20:13:29.000Z - 11 days ago

uniQure announces $150M offering of common stock


uniQure Announces $150 Million Proposed Public Offering

Jun 22, 2026, 4:01 PM EDT - 11 days ago

uniQure Announces $150 Million Proposed Public Offering


uniQure price target raised to $70 from $36 at Leerink

2026-06-18T11:31:03.000Z - 16 days ago

uniQure price target raised to $70 from $36 at Leerink


uniQure price target raised to $65 from $35 at RBC Capital

2026-06-18T11:18:09.000Z - 16 days ago

uniQure price target raised to $65 from $35 at RBC Capital


uniQure upgraded to Overweight from Equal Weight at Barclays

2026-06-18T11:12:32.000Z - 16 days ago

uniQure upgraded to Overweight from Equal Weight at Barclays


uniQure price target raised to $46 from $14 at Goldman Sachs

2026-06-18T10:27:49.000Z - 16 days ago

uniQure price target raised to $46 from $14 at Goldman Sachs


What made uniQure stock nearly double on Wednesday?

Jun 17, 2026, 11:32 AM EDT - 17 days ago

What made uniQure stock nearly double on Wednesday?


UniQure Stock (QURE) Rockets on an FDA Update

2026-06-17T14:56:04.000Z - 17 days ago

UniQure Stock (QURE) Rockets on an FDA Update


This Biotech Stock Is Surging 66% on Surprise Good News From FDA

Jun 17, 2026, 10:10 AM EDT - 17 days ago

This Biotech Stock Is Surging 66% on Surprise Good News From FDA


uniQure Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 2 months ago

uniQure Earnings Call Transcript: Q1 2026


uniQure Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 2 months ago

uniQure Earnings release: Q1 2026


uniQure Quarterly report: Q1 2026

May 5, 2026, 8:30 AM EDT - 2 months ago

uniQure Quarterly report: Q1 2026


uniQure to Announce First Quarter 2026 Financial Results

Apr 28, 2026, 7:05 AM EDT - 2 months ago

uniQure to Announce First Quarter 2026 Financial Results


uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

uniQure Proxy statement: Proxy filing


uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

uniQure Proxy statement: Proxy filing


uniQure Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

uniQure Proxy statement: Proxy filing


uniQure Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 4 months ago

uniQure Transcript: TD Cowen 46th Annual Health Care Conference


uniQure Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:00 AM EST - 4 months ago

uniQure Earnings Call Transcript: Q4 2025


uniQure Earnings release: Q4 2025

Mar 2, 2026, 8:00 AM EST - 4 months ago

uniQure Earnings release: Q4 2025


uniQure Annual report: Q4 2025

Mar 2, 2026, 8:00 AM EST - 4 months ago

uniQure Annual report: Q4 2025


uniQure to Announce 2025 Financial Results

Feb 23, 2026, 7:05 AM EST - 4 months ago

uniQure to Announce 2025 Financial Results


uniQure Slides: Corporate presentation

Jan 13, 2026, 7:00 AM EST - 6 months ago

uniQure Slides: Corporate presentation


uniQure Announces Type A Meeting Scheduled with FDA

Jan 9, 2026, 7:05 AM EST - 6 months ago

uniQure Announces Type A Meeting Scheduled with FDA


Benalish
Benalish Jul. 3 at 1:07 AM
1 · Reply
free2dream
free2dream Jul. 2 at 8:14 PM
$SRPT correction : SAREPTA SHOULD BE VALUED HIGHER THAN $MRNA ! Their progress in Huntington disease is ahead of $QURE . ELEVIDYS and other DMD therapies are extremely undervalued. Charge more money for it. It only cost investors $20B to develop, 2 kids died and investors got wiped out. TOTAL BULLSHIT !
2 · Reply
free2dream
free2dream Jul. 2 at 7:58 PM
$SRPT YOU AINT GOING TO FIND A BIOTECH COMPANY THIS UNDERVALUED ! $2B ARKET CAP on $2B market sale and right neck to neck with $QURE on huntington research. SAREPTA INVESTORS MOVE YOUR ASKS WAY UP , $200+
1 · Reply
Dkll303
Dkll303 Jul. 2 at 4:27 PM
$QURE $25 on the horizon once again …Matt will make sure of that !!! For his Leerink friends ..
0 · Reply
Dkll303
Dkll303 Jul. 2 at 4:26 PM
$QURE appears the SHIT didn’t stick !!!! But then Matt tries anything , even selling pieces to keep his ass from cold calling again
0 · Reply
Stef_Gee
Stef_Gee Jul. 2 at 2:09 PM
$QURE Struggling under VWAP ...
0 · Reply
MABA1
MABA1 Jul. 2 at 1:44 PM
$QURE I’m in
0 · Reply
LotOfAction
LotOfAction Jul. 2 at 12:05 PM
$QURE Sold half from 17s, letting the other half ride
0 · Reply
stu4
stu4 Jul. 1 at 10:48 AM
$QURE will Matt Kapu-shit throw shit against the wall again today …to see if it sticks ???? Probably All his friends like those of TRUMP , left for the holidays , ( ya know scum brokers that he was for years ) and the stock will drift ..no phone whispers to his click of broker friends
1 · Reply
stu4
stu4 Jul. 1 at 1:47 AM
$QURE ANOTHER BFD !!!
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 30 at 4:26 PM
uniQure Epilepsy Gene Therapy Data Draws Investor Focus https://ow.ly/qVhZ50ZiMgq uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next. $QURE
0 · Reply
JFais
JFais Jun. 30 at 3:24 PM
Coffee at the Close replay $XBI https://youtu.be/IkukIiodfsU?si=gXmXi96Oo9KezLLa A few topics covered: -How we respond to biotech "gut punches" / negative news (choose logic over emotion) $OMER -Regulatory reversals & impact on sentiment $QURE -How @JoseRestonVA views selling pressure (examples with $APGE and $BHVN 1.0) -Our💡moment (less is more vs overtrading) -Importance of waiting for the right pitches vs chasing at highs
1 · Reply
stu4
stu4 Jun. 30 at 1:14 PM
$QURE money is in , next you will read Matt Kapu-shit sold shares … Deja vue here While HC wain-wrong says buy the pos to $80 … like their call on $SOL to $36 and $2 today !!!! Leerink is the new and somewhat improved HC Wainwrong !!
0 · Reply
free2dream
free2dream Jun. 30 at 1:06 PM
$SRPT 1.7B market cap with $2B annual sales. THE BIGGEST BARGAIN in the entire market. even revenueless $QURE is 2x the market cap . Sarepta is a $200 stock
0 · Reply
Bogy99
Bogy99 Jun. 30 at 12:50 PM
$MGTX re-ratings are painful for those on the sidelines and of course shorts. I begged those shorts to cover below $10. Was a gift I said. They didn’t listen. 5.5mm shares short. What to expect ? Thanks to new FDA and our friends at $QURE , the new baseline valuation is 1x sales. For Meira that is $5B or ~ $50 per share. Because the shorts are dumb and don’t listen , they will likely drive us to that $50 number sooner rather than later. If you’re on the sidelines watching. Don’t wait, act now. You have a 4-5 bagger (12 months max) just waiting for you. As always, I do wish you well. (Unless you’re short). You guys are screwed!
1 · Reply
Quantumup
Quantumup Jun. 30 at 12:44 PM
BTIG (pre-RPD news)⬆️ $MNPR's PT to $117 (was $104), reiterated Buy and said, We believe MNPR's regulatory outlook has improved materially ahead of a planned mid-year NDA submission for ALXN1840 for the treatment of Wilson's Disease (WD). $QURE $RGNX AZN RARE BTIG added—The recent regulatory reversals for rare disease therapies including those by uniQure (QURE, Not Rated) and RegenxBio (RGNX, Not Rated) signal a turning of the page under the current FDA led by Acting Commissioner Kyle Diamantas. More importantly, the agency issued draft guidance reaffirming that a single, high-quality ph 3 trial supported by confirmatory evidence may be sufficient for drug approval, boding well for MNPR. We increase our PoS for ALXN1840 in our model on this basis, driving our new $117 PT.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 29 at 7:46 PM
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment, Gets Buy Rating https://ow.ly/wAtx50ZiqxP uniQure N.V. ( $QURE ) announced initial six-month data for AMT-260 treating refractory epilepsy, with three of six patients showing 79-100% seizure reduction.
0 · Reply
Stockswingalert
Stockswingalert Jun. 29 at 6:32 PM
$CLPT if you late here to the 💎 party 🔐 sponsored by #lockedintrading @Stockswingalert LLC My good exclusive karma and way to pay it forward for my OG crowd on here cc @Stocktwits 🙏🎯👇💰 for ONLY free.99 🤝🤝🤝 Is to watch the gap fill here at $19.68 ☢️📈 In a world selling gold (gene therapy), sometimes the better bet is to buy the shovels… In this case that is this right here 👇👇👇 cc $QURE $CRSP $RHHBY #roche
0 · Reply
stu4
stu4 Jun. 29 at 2:34 PM
$QURE getting out Leerink ? Flippers , sad souls
0 · Reply
Thinkingman91
Thinkingman91 Jun. 29 at 2:00 PM
$CLPT $QURE $SRRK I’ve given you 3 since December and all went 50% or more. Im a chart specialist focusing on returns 🫡
2 · Reply
free2dream
free2dream Jun. 29 at 1:45 PM
$SPY LOAD UP ON $SRPT THE REAL SQUEEZE IS COMING 25% short float, pathetic 1.7B market cap while $QURE is at $3.3B . SAREPTA WIL GAP UP TO $60S easily
0 · Reply
free2dream
free2dream Jun. 29 at 1:36 PM
$SRPT ANALYST MORONS WAKE THE FXCK UP ! $QURE IS WORTH 2X SAREPTA ? YOU MUST BE JOKING
0 · Reply